Peter M. Fleischut

Chief Innovation Officer & Chief Medical Operating Officer, New York-Presbyterian Hospital

Peter M. Fleischut, MD, is Chief Innovation Officer & Chief Medical Operating Officer of NewYork-Presbyterian Hospital where he is responsible for the DHK ambulatory center and enterprise integration, innovation and pharmacy. He joined NewYork-Presbyterian Hospital in 2006 and has held roles as Medical Director of the operating rooms, Deputy Quality Patient Safety Officer, Founding Director of the Center for Perioperative Outcomes, Chief Medical Information Officer and Vice Chairman for the Department of Anesthesiology.  Dr. Fleischut retains his appointment as Associate Professor of Anesthesiology.
Dr. Fleischut received his MD, Alpha Omega Alpha from Jefferson Medical College and graduated from Wharton School at the University of Pennsylvania, completed his residency training in Anesthesiology at NewYork-Presbyterian/Weill Cornell Medicine. He has received several awards, including the David A. Leach Award for Innovation in Quality from the Accreditation Council on Graduate Medical Education, the John M. Eisenberg Patient Safety and Quality Award from the National Quality Forum and The Joint Commission, and the Weill Cornell Medical College Healthcare Leadership Award.  In 2013, he was named one of twelve Up and Comers by Modern Healthcare, recognizing healthcare leaders under the age of 40, and was also named Physician of the Year at NYP/Weill Cornell. In 2014, he was named one of the 25 healthcare leaders under 40 by Becker’s Hospital Review. In 2015, he received the InformationWeek Elite 100 Award, the City & State Reports Corporate Social Responsibility Vanguard Award, and was named to City & State Reports Responsible 100 List.

My Sessions

Roundtable | Pharma Weighs In – Tech Innovations & How to Partner

Among other topics, this session will cover: Working with an informed consumer The ‘retail mindset’ transforming healthcare How big pharma partners with startups What are the new and innovative technologies that are appealing to big pharma How has pharma’s partnership strategy evolved over time? What does Pharma care about most while looking at early stage investments? […]